Details Basic Details Status Ongoing Last Updated Thursday, November 19, 2026 Original Posting Date Thursday, June 12, 2025 Health Outcome(s) non-arteritic anterior ischemic optic neuropathy Purpose Drug and Outcome Analysis Meets requirements of FD&C Act Sec 505(o) prior to requiring a PMR No Analytic Code Link(s) (1) Study Protocol: Risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Following Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Use in Patients with Type 2 Diabetes Mellitus Regulatory Link(s) (1) FDA Safety Communication: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition